{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:59:59Z","timestamp":1787821199228,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer patient pathways (CPPs) were implemented in Norway to reduce unnecessary waiting times, regional variations, and to increase the predictability of cancer care for the patients. This study aimed to determine if 70% of cancer patients started treatment within the recommended time frames, and to identify potential delays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients registered with a colorectal, lung, breast, or prostate cancer diagnosis at the Cancer Registry of Norway in 2015\u20132016 were linked with the Norwegian Patient Registry and Statistics Norway. Adjusting for sociodemographic variables, multivariable quantile (median) regressions were used to examine the association between place of residence and median time to start of examination, treatment decision, and start of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 20\u00a0668 patients. The proportions of patients who went through the CPP within the recommended time frames were highest among colon (84%) and breast (76%) cancer patients who underwent surgery and lung cancer patients who started systemic anticancer treatment (76%), and lowest for prostate cancer patients who underwent surgery (43%). The time from treatment decision to start of treatment was the main source of delay for all cancers. Travelling outside the resident health trust prolonged waiting time and was associated with a reduced odds of receiving surgery and radiotherapy for lung and rectal cancer patients, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Achievement of national recommendations of the CCP times differed by cancer type and treatment. Identified bottlenecks in the pathway should be targeted to decrease waiting times. Further, CPP guidelines should be re-examined to determine their ongoing relevance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09306-9","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T12:04:20Z","timestamp":1646049860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015\u20132016"],"prefix":"10.1186","volume":"22","author":[{"given":"Yngvar","family":"Nilssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Terje","family":"Brustugun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Tandberg","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne G.","family":"Guren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Skaaheim","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Naume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"9306_CR1","volume-title":"Cancer in Norway 2020 - Cancer incidence, mortality, survival and prevalence in Norway","author":"Cancer Registry of Norway","year":"2021","unstructured":"Cancer Registry of Norway. Cancer in Norway 2020 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2021."},{"key":"9306_CR2","unstructured":"Engholm G, Ferlay J, Christensen N, Kejs AMT, Johannesen TB, Khan S, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.2 (16.12.2015) Association of the Nordic Cancer Registries. Danish Cancer Society. Available from: http:\/\/www.ancr.nu. Accessed 25 Feb 2021."},{"key":"9306_CR3","first-page":"h5102","volume":"351","author":"H Moller","year":"2015","unstructured":"Moller H, Gildea C, Meechan D, Rubin G, Round T, Vedsted P. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. BMJ (Clinical research ed). 2015;351:h5102.","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"9306_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.healthpol.2011.11.001","volume":"105","author":"HB Probst","year":"2012","unstructured":"Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians\u2013a national Danish project. Health policy (Amsterdam, Netherlands). 2012;105(1):65\u201370.","journal-title":"Health policy (Amsterdam, Netherlands)"},{"issue":"1\u20132","key":"9306_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.healthpol.2013.09.012","volume":"113","author":"HB Dyrop","year":"2013","unstructured":"Dyrop HB, Safwat A, Vedsted P, Maretty-Nielsen K, Hansen BH, Jorgensen PH, et al. Cancer Patient Pathways shortens waiting times and accelerates the diagnostic process of suspected sarcoma patients in Denmark. Health policy (Amsterdam, Netherlands). 2013;113(1\u20132):110\u20137.","journal-title":"Health policy (Amsterdam, Netherlands)"},{"key":"9306_CR6","unstructured":"Helse- og omsorgsdepartementet. Sammen - mot kreft. Nasjonal kreftstrategi 2013\u20132017. Available from: https:\/\/www.iccp-portal.org\/system\/files\/plans\/kreftstrategien_2013.pdf. Accessed 22 Feb\u00a02022."},{"key":"9306_CR7","unstructured":"Helsedirektoratet. Pakkeforl\u00f8p for tykk- og endetarmskreft. Available from: https:\/\/www.helsedirektoratet.no\/pakkeforlop\/tykk-og-endetarmskreft. Accessed 25 Feb\u00a02020."},{"key":"9306_CR8","unstructured":"Helsedirektoratet. Pakkeforl\u00f8p for lungekreft. Available from: https:\/\/www.helsedirektoratet.no\/pakkeforlop\/lungekreft. Accessed 25 Feb\u00a02020."},{"key":"9306_CR9","unstructured":"Helsedirektoratet. Pakkeforl\u00f8p for brystkreft. Available from: https:\/\/www.helsedirektoratet.no\/pakkeforlop\/brystkreft. Accessed 25 Feb\u00a02020."},{"key":"9306_CR10","unstructured":"Helsedirektoratet. Pakkeforl\u00f8p for prostatakreft. Available from: https:\/\/www.helsedirektoratet.no\/pakkeforlop\/Prostatakreft. Accessed 25 Feb\u00a02020."},{"key":"9306_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canep.2019.05.004","volume":"61","author":"Y Nilssen","year":"2019","unstructured":"Nilssen Y, Brustugun OT, Tandberg Eriksen M, Gulbrandsen J, SkaaheimHaug E, Naume B, et al. Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway. Cancer Epidemiol. 2019;61:59\u201369.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"9306_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12885-020-06979-y","volume":"20","author":"Y Nilssen","year":"2020","unstructured":"Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, M\u00f8ller B. Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015\u20132016. BMC Cancer. 2020;20(1):488.","journal-title":"BMC Cancer"},{"key":"9306_CR13","unstructured":"Helsedirektoratet. Pakkeforl\u00f8p for kreft - Sentrale indikatorer. Available from: https:\/\/statistikk.helsedirektoratet.no\/bi\/Dashboard\/71613538-62de-4ab2-8409-8638fc6c25db?e=false&vo=viewonly. Accessed 26 June\u00a02021."},{"issue":"6","key":"9306_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ijc.29875","volume":"138","author":"Y Nilssen","year":"2016","unstructured":"Nilssen Y, Strand TE, Fjellbirkeland L, Bartnes K, Brustugun OT, O\u2019Connell DL, et al. Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage. Int J of Cancer J Int du Cancer. 2016;138(6):1350\u201360.","journal-title":"Int J of Cancer J Int du Cancer"},{"issue":"9","key":"9306_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1080\/0284186X.2018.1468087","volume":"57","author":"LM \u00c5sli","year":"2018","unstructured":"\u00c5sli LM, Myklebust T, Kval\u00f8y SO, Jetne V, M\u00f8ller B, Levernes SG, et al. Factors influencing access to palliative radiotherapy: a Norwegian population-based study. Acta oncologica (Stockholm, Sweden). 2018;57(9):1250\u20138.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"7","key":"9306_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","volume":"45","author":"IK Larsen","year":"2009","unstructured":"Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer (Oxford, England\u202f: 1990). 2009;45(7):1218\u201331.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"9306_CR17","volume-title":"Omfang og Utvikling av det Selv-betalende Markedet for Private Spesialisthelsetjenester i Norge [Scope and Development of the Private Spending on Healthcare for Private Healthcare in Norway]","author":"S Kastpersen","year":"2010","unstructured":"Kastpersen S, Kalseth B. Omfang og Utvikling av det Selv-betalende Markedet for Private Spesialisthelsetjenester i Norge [Scope and Development of the Private Spending on Healthcare for Private Healthcare in Norway]. Trondheim: SINTEF; 2010."},{"issue":"3","key":"9306_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ijc.27651","volume":"132","author":"S Walters","year":"2013","unstructured":"Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP. Comparability of stage data in cancer registries in six countries: lessons from the International cancer benchmarking partnership. Int J Cancer J International du Cancer. 2013;132(3):676\u201385.","journal-title":"Int J Cancer J International du Cancer"},{"issue":"4","key":"9306_CR19","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer part 1: screening diagnosis and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"key":"9306_CR20","unstructured":"Nasjonalt kvalitetsregister for prostatakreft. \u00c5rsrapport 2019 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft. Kreftregisteret. Oslo, 2020."},{"key":"9306_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.breast.2017.12.001","volume":"38","author":"IK Larsen","year":"2018","unstructured":"Larsen IK, Myklebust TA, Johannesen TB, Moller B, Hofvind S. Stage-specific incidence and survival of breast cancer in Norway: the implications of changes in coding and classification practice. Breast. 2018;38:107\u201313.","journal-title":"Breast"},{"key":"9306_CR22","volume-title":"Stata statistical software: release 16","author":"StataCorp.","year":"2019","unstructured":"StataCorp. Stata statistical software: release 16. College Station, TX: StataCorp LLC; 2019."},{"key":"9306_CR23","unstructured":"Nasjonalt kvalitetsregister for tykk- og endetarmskreft. \u00c5rsrapport 2019 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for tykk- og endetarmskreft. Kreftregisteret; Oslo, 2020."},{"key":"9306_CR24","unstructured":"Helsedirektoratet (2017). Nasjonalt handlingsprogram med retningslinjer for diagnostikk behandling og oppf\u00f8lging av kreft i tykktarm og endetarm [nettdokument]. Updated: 04.05.2021. Available from: https:\/\/www.helsedirektoratet.no\/retningslinjer\/kreft-i-tykktarm-og-endetarm-handlingsprogram. Accessed 20 June\u00a02021."},{"issue":"10","key":"9306_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3109\/0284186X.2015.1034876","volume":"54","author":"MG Guren","year":"2015","unstructured":"Guren MG, K\u00f8rner H, Pfeffer F, Myklebust T, Eriksen MT, Edna TH, et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993\u20132010. Acta oncologica (Stockholm, Sweden). 2015;54(10):1714\u201322.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"1","key":"9306_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/bjs.5576","volume":"94","author":"MH Hansen","year":"2007","unstructured":"Hansen MH, Kjaeve J, Revhaug A, Eriksen MT, Wibe A, Vonen B. Impact of radiotherapy on local recurrence of rectal cancer in Norway. Br J Surg. 2007;94(1):113\u20138.","journal-title":"Br J Surg"},{"key":"9306_CR27","unstructured":"Nasjonalt kvalitetsregister for brystkreft. \u00c5rsrapport 2019 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Kreftregisteret. Oslo, 2020."},{"issue":"7","key":"9306_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1001\/jamasurg.2021.1438","volume":"156","author":"J de Boniface","year":"2021","unstructured":"de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish NATIonal 6-year follow-up of 48 986 women. JAMA Surg. 2021;156(7):628\u201337.","journal-title":"JAMA Surg"},{"issue":"15","key":"9306_CR29","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415\u201324.","journal-title":"N Engl J Med"},{"issue":"8","key":"9306_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00345-018-2570-6","volume":"37","author":"K Aas","year":"2019","unstructured":"Aas K, Foss\u00e5 SD, Kv\u00e5le R, M\u00f8ller B, Myklebust T, Vlatkovic L, et al. Is time from diagnosis to radical prostatectomy associated with oncological outcomes? World J Urol. 2019;37(8):1571\u201380.","journal-title":"World J Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T02:07:47Z","timestamp":1646100467000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9306"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09306-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Norwegian Regional Ethics Committee concluded that no approval was needed for this study (reference number: 2017\/428REK s\u00f8r-\u00f8st A). Thus, they gave the authors exemption from the statutory duty of confidentiality. The approval of handling indirect identifiable data was obtained from the Data Protection Officer (PVO) (reference number: 2017\/6597). All methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}